Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00310037 · ClinicalTrials.gov registry record · Phase 2

Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma

A Phase 2 study of Mantle Cell Lymphoma, sponsored by Alliance for Clinical Trials in Oncology.

Completed
Registry status
Phase 2
Development phase
151
Enrollment target
20
Study locations

NCT00310037 is a Phase 2 study of Mantle Cell Lymphoma that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 151 participants, above the 103-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (47% higher). The trial reports 20 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00310037, a Phase 2 study of Mantle Cell Lymphoma, has completed, sponsored by Alliance for Clinical Trials in Oncology.

COMPLETED
Registry status
Phase 2
Development phase
151 participants
Enrollment target
20
Study locations

Study Summary

This randomized phase II trial studies how well bortezomib works when given after combination chemotherapy, rituximab, and an autologous stem cell transplant in treating patients with mantle cell lymphoma. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) together with an autologous stem cell transplant may allow more chemotherapy to be given so that more cancer cells are killed. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving bortezomib after combination chemotherapy, monoclonal antibody therapy, and an autologous stem cell transplant may kill any remaining cancer cells or keep the cancer from coming back.

Conditions Studied

Mantle Cell Lymphoma

Interventions

  • DRUG bortezomib

Study Locations (20)

Illinois

  • Illinois CancerCare - Bloomington - Bloomington
  • St. Joseph Medical Center - Bloomington
  • Graham Hospital - Canton
  • Illinois CancerCare - Canton - Canton
  • Illinois CancerCare - Carthage - Carthage
  • Memorial Hospital - Carthage
  • University of Chicago Cancer Research Center - Chicago
  • Eureka Community Hospital - Eureka
  • Illinois CancerCare - Eureka - Eureka
  • Galesburg Clinic, PC - Galesburg
  • Illinois CancerCare - Galesburg - Galesburg
  • Illinois CancerCare - Havana - Havana
  • Mason District Hospital - Havana
  • Illinois CancerCare - Kewanee Clinic - Kewanee
  • Illinois CancerCare - Macomb - Macomb
  • McDonough District Hospital - Macomb
  • Illinois CancerCare - Monmouth - Monmouth
  • OSF Holy Family Medical Center - Monmouth
  • BroMenn Regional Medical Center - Normal

California

  • UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco

Trial Details

FieldValue
Enrollment Target 151 participants
Start Date 2006-06
Est. Completion 2022-06
Phase Phase 2

Sponsor

Alliance for Clinical Trials in Oncology

446 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00310037

The ClinicalTrials.gov registry entry for NCT00310037 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 151 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 103-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (47% higher). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Mantle Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which bortezomib is the first listed.

NCT00310037 reports 20 study locations spanning 2 distinct geographic areas - top geographies include Illinois, California.

Frequently Asked Questions

What is clinical trial NCT00310037 about?

NCT00310037 is a clinical study titled "Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma". This randomized phase II trial studies how well bortezomib works when given after combination chemotherapy, rituximab, and an autologous stem cell transplant in treating patients with mantle cell lymphoma. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell...

What is the current status of trial NCT00310037?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 151 participants. The study started on 2006-06. Estimated completion is 2022-06.

What conditions does trial NCT00310037 study?

This clinical trial studies the following conditions: Mantle Cell Lymphoma.

What interventions are being tested in trial NCT00310037?

The interventions under investigation include: bortezomib (DRUG).

Who is sponsoring clinical trial NCT00310037?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00310037 being conducted?

This trial has 20 study locations across California, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Mantle Cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Mantle Cell Lymphoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.